Stratos Wealth Partners LTD. Purchases Shares of 13,166 Organon & Co. (NYSE:OGN)

Stratos Wealth Partners LTD. purchased a new stake in shares of Organon & Co. (NYSE:OGN) during the fourth quarter, Holdings Channel reports. The fund purchased 13,166 shares of the company’s stock, valued at approximately $190,000.

A number of other institutional investors have also bought and sold shares of the company. Kahn Brothers Group Inc. boosted its position in Organon & Co. by 0.6% during the fourth quarter. Kahn Brothers Group Inc. now owns 62,634 shares of the company’s stock valued at $1,749,000 after acquiring an additional 366 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund boosted its position in Organon & Co. by 5.2% during the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 9,114 shares of the company’s stock valued at $213,000 after acquiring an additional 449 shares during the last quarter. Fairfield Bush & CO. boosted its position in shares of Organon & Co. by 3.0% during the 1st quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock worth $569,000 after purchasing an additional 481 shares in the last quarter. Cresset Asset Management LLC boosted its position in shares of Organon & Co. by 3.7% during the 1st quarter. Cresset Asset Management LLC now owns 13,969 shares of the company’s stock worth $488,000 after purchasing an additional 493 shares in the last quarter. Finally, Capital Research Global Investors boosted its position in shares of Organon & Co. by 0.7% during the 1st quarter. Capital Research Global Investors now owns 71,903 shares of the company’s stock worth $2,512,000 after purchasing an additional 513 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Insider Activity at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver purchased 2,720 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average price of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now owns 15,181 shares in the company, valued at $278,723.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.17% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group increased their price objective on shares of Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 20th.

Organon & Co. Price Performance

OGN stock opened at $17.80 on Wednesday. The stock has a market capitalization of $4.55 billion, a PE ratio of 4.45, a price-to-earnings-growth ratio of 0.83 and a beta of 0.82. The company’s 50-day moving average is $17.93 and its 200-day moving average is $15.59. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.79.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.55 billion. On average, analysts anticipate that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were given a $0.28 dividend. The ex-dividend date was Friday, February 23rd. This represents a $1.12 annualized dividend and a yield of 6.29%. Organon & Co.’s payout ratio is 28.00%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.